Subsequent Events (Details) - USD ($)					1 Months Ended							9 Months Ended
	Nov. 09, 2017	Nov. 07, 2017	Jul. 11, 2017	Apr. 21, 2017	Nov. 30, 2017	Oct. 31, 2017	Oct. 21, 2017	Oct. 17, 2017	Oct. 16, 2017	Jun. 30, 2017	Jan. 31, 2017	Sep. 30, 2017	Jun. 28, 2017	Dec. 31, 2016
Subsequent Events (Textual)
Sale of common stock shares			300,000
Aggregate common stock, shares										2,000,000	3,000,000
Common stock, par value												$ 0.025		$ 0.025
Underwriting agreement, description												Pursuant to the Underwriting Agreement, the Company granted the Underwriters a 45-day option to purchase up to an additional 300,000 shares of Common Stock and/or 75,000 Warrants to purchase shares of Common Stock with an exercise price of $1.90 per share.
Offering expenses												$ 1,200,000
Underwriting Agreement [Member]
Subsequent Events (Textual)
Aggregate common stock, shares				1,083,017
Offering price per share													$ 1.75
Subsequent Event [Member]
Subsequent Events (Textual)
Aggregate common stock, shares								110,000
Warrants issued								1,650,000
Capital leases description						The total cost of the equipment is approximately $2,900,000, 20% paid up front and the remaining balance payable over the next 36 months at an annual interest rate of 5.95%.
Subsequent Event [Member] | DxT Medical, LLC [Member]
Subsequent Events (Textual)
Dividends rate									100.00%
Subsequent Event [Member] | Series E Preferred Stock [Member]
Subsequent Events (Textual)
Common stock, par value							$ 1.00
Exercise price								$ 1.20
Underwriting agreement, description					The Company received $2,290,000 in funding (the "Funding") in connection with a private placement offering to accredited investors (the "Offering") of up to $3,000,000 of units (the "Units"), with each Unit comprised of (i) one (1) share of Series E Preferred Stock, par value $0.001 per share (the "Series E Preferred Stock") and (ii) fifteen (15) warrants (the "Warrants") to purchase shares of the Company's common stock. In connection with the Funding, the Company entered into a definitive securities purchase agreement (the "Securities Purchase Agreement") with accredited investors (the "Investor"), and an aggregate of 229,000 shares of Series E Preferred Stock and 3,435,000 Warrants was issued, for aggregate gross proceeds to the Company of $2,290,000. The Warrants are five year warrants to purchase shares of Common Stock at an exercise price of $1.20 per share, exercisable beginning six months after the date of issuance thereof. The Warrants provide for cashless exercise to the extent that there is no registration statement available for the underlying shares of Common Stock.	The Company received $2,290,000 in funding (the "Funding") in connection with a private placement offering to accredited investors (the "Offering") of up to $3,000,000 of units (the "Units"), with each Unit comprised of (i) one (1) share of Series E Preferred Stock, par value $0.001 per share (the "Series E Preferred Stock") and (ii) fifteen (15) warrants (the "Warrants") to purchase shares of the Company's common stock. In connection with the Funding, the Company entered into a definitive securities purchase agreement (the "Securities Purchase Agreement") with accredited investors (the "Investor"), and an aggregate of 229,000 shares of Series E Preferred Stock and 3,435,000 Warrants was issued, for aggregate gross proceeds to the Company of $2,290,000. The Warrants are five year warrants to purchase shares of Common Stock at an exercise price of $1.20 per share, exercisable beginning six months after the date of issuance thereof. The Warrants provide for cashless exercise to the extent that there is no registration statement available for the underlying shares of Common Stock.
Preferred stock established							300,000
Preferred stock, par value							$ 10.00
Dividends rate							20.00%
Subsequent Event [Member] | Placement Agent [Member]
Subsequent Events (Textual)
Aggregate common stock, shares					167,500	167,500
Aggregate gross proceeds issuance to company								$ 1,100,000
Placement agents aggregate cash fee					$ 141,000	$ 141,000
Offering expenses					$ 2,000,000	$ 2,000,000
Subsequent Event [Member] | Purchase Agreement [Member]
Subsequent Events (Textual)
Aggregate common stock, shares									350,000
Common stock, par value									$ 0.025
Subsequent Event [Member] | American Science and Technology Corporation [Member]
Subsequent Events (Textual)
License agreement, description	The License Agreement, effective January 1, 2018, AST will grant to Innovations an exclusive commercial license in, to and under certain licensed patents to make, have made, use, offer to sell, market, advertise, sell, dispose of, and import certain licensed products, for a term of 24 months, unless terminated earlier. Pursuant to the License Agreement, on January 1, 2018, Innovations will pay to AST $200,000 and the Company will issue to AST 200,000 shares of the Company's restricted common stock, and, beginning effective January 1, 2019, Innovations will pay to AST a monthly license fee of $50,000.
Lease agreement, description	The Lease, on January 1, 2018, Innovations will pay to AST $300,000 and the Company will issue to AST 300,000 shares of the Company's restricted common stock, and, beginning effective January 1, 2019, Innovat6ions will pay to AST a monthly rent of $75,000. Pursuant to the Lease, Innovations and AST entered into an Option Agreement (the "Option"), granting Innovations the option to purchase the assets of AST for $2,500,000, in addition to certain royalty and other future payments.
Subsequent Event [Member] | Investment Agreement [Member]
Subsequent Events (Textual)
Aggregate common stock, shares		242,718
Description of investment agreement		Pursuant to the terms of the Investment Agreement, for a period of twenty-four months commencing on the date of execution and delivery of the Investment Agreement, YA has committed to purchase up to $10,000,000 (the "Commitment Amount") of the Company's common stock, par value $0.025 per share (the "Advance Shares"). At its option, the Company may require YA to purchase the Advance Shares at the price of $1.00 per Advance Share, subject to and in accordance with the terms and conditions of the Investment Agreement, including, without limitation, the requirement that the Advance Shares be registered and that the Market Price (as defined in the Investment Agreement) is at least $1.20. The Company is not required to make any minimum sale of the Advance Shares and there is no applicable non-usage fee. The Company may terminate the Investment Agreement at any time, provided there are no Advance Shares required to be delivered and no other amounts are owed by the Company to YA, and, in the event that such termination occurs prior to May 8, 2018.
Commitment fee		$ 250,000
Termination fee		$ 100,000